• Wondering whether CRISPR Therapeutics at US$55.18 is priced for its potential or already demanding a premium? This article focuses squarely on what the current market value might be telling you.
• The stock has seen a 41.1% return over the last year, with a 30 day return of 18.8%, while also showing shorter term volatility such as a 1% decline over the last week and a 5 year return of negative 58.2%.
• Recent headlines around CRISPR Therapeutics continue to keep attention on the company, including ongoing discussion of its gene editing platform and its position among listed biotech peers. This backdrop helps explain why sentiment can swing quickly as investors reassess both opportunity and risk.
• CRISPR Therapeutics currently holds a valuation score of 3 out of 6. The rest of this article will compare different valuation approaches before finishing with a way to frame valuation that goes beyond any single model.

Approach 1: CRISPR Therapeutics Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow model takes projected future cash flows and discounts them back to today’s dollars to estimate what the business might be worth right now.

For CRISPR Therapeutics, the 2 Stage Free Cash Flow to Equity model starts from last twelve month free cash flow of about $345.4 million outflow. Analyst inputs and extrapolated estimates then project free cash flow moving to $204.5 million by 2030. The path includes both negative and positive cash flow years along the way, all expressed in dollars and discounted back to today.

Combining these cash flow projections produces an estimated intrinsic value of about $184.14 per share. Compared with the recent share price of $55.18, this DCF output points to an implied discount of roughly 70.0%. On this model, the stock screens as materially undervalued.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests CRISPR Therapeutics is undervalued by 70.0%. Track this in your watchlist or portfolio, or discover 54 more high quality undervalued stocks.

Approach 2: CRISPR Therapeutics Price vs Book

Price to Book, or P/B, is often used for companies where earnings are less consistent, because it focuses on what you are paying relative to the net assets on the balance sheet rather than current profits.

In general, higher growth expectations and lower perceived risk can support a higher P/B multiple, while slower growth or higher uncertainty usually point to a lower, more conservative range. That context helps you judge whether a given P/B looks stretched or restrained.

CRISPR Therapeutics currently trades on a P/B of 2.77x. This is above the Biotechs industry average of about 2.39x and above the peer group average of 22.82x, which is very high. Simply Wall St also uses a proprietary “Fair Ratio” for P/B, which estimates what a reasonable multiple might be for this specific company after considering factors such as its earnings profile, growth outlook, risks, profit margins, industry and market capitalization.

This Fair Ratio approach can be more tailored than a simple comparison with peers or the broad industry, because it adjusts for the company’s own fundamentals instead of assuming all biotechs deserve similar multiples. In this case, there is no Fair Ratio available, so it is not possible to state whether the current 2.77x P/B suggests CRISPR Therapeutics is under or overvalued.

Result: ABOUT RIGHT

P/B ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 17 top founder-led companies.

Upgrade Your Decision Making: Choose your CRISPR Therapeutics Narrative

Earlier it was mentioned that there is an even better way to understand valuation. This is where Narratives come in, giving you a simple story that links what you believe about a company to the numbers behind it.

A Narrative is your structured view of a business, where you set assumptions for future revenue, earnings and margins, then connect those assumptions to an estimated fair value that sits behind the share price you see on screen.

On Simply Wall St, Narratives are available on the Community page and are used by millions of investors as an accessible tool that ties a company’s story to a financial forecast and then to a clear fair value that can be compared with the current price to help decide whether it may be a time to wait, add or trim.

These Narratives refresh when new information such as news or earnings is added, so the fair value view is not static. For CRISPR Therapeutics that can mean one investor building a cautious Narrative that focuses on ongoing cash outflows, while another builds a more optimistic Narrative that prioritizes the gene editing platform and longer term commercial potential.

Do you think there's more to the story for CRISPR Therapeutics? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.